Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118940772 | 11894077 | 2 | F | 19980503 | 20160826 | 20160107 | 20160827 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-B040397 | BRISTOL MYERS SQUIBB | 0.00 | DY | M | Y | 3.20000 | KG | 20160827 | OT | GB | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118940772 | 11894077 | 1 | PS | ZERIT | STAVUDINE | 1 | Transplacental | 60 MG, QD | U | NOT APPLICABLE | 20412 | 60 | MG | CAPSULE, HARD | QD | ||||
| 118940772 | 11894077 | 2 | SS | VIDEX | DIDANOSINE | 1 | Transplacental | 300 MG, QD | U | NOT REPORTED | 0 | 300 | MG | TABLET | QD | ||||
| 118940772 | 11894077 | 3 | SS | VIRAMUNE | NEVIRAPINE | 1 | Transplacental | DOSE UNIT: TABLET EXPOSURE INITIATED IN WEEK 24 OF GESTATION. | U | NOT REPORTED | 0 | 2 | DF | QD | |||||
| 118940772 | 11894077 | 4 | SS | CRIXIVAN | INDINAVIR SULFATE | 1 | Transplacental | UNK | U | NOT REPORTED | 0 | ||||||||
| 118940772 | 11894077 | 5 | SS | EPIVIR | LAMIVUDINE | 1 | Transplacental | UNK | U | NOT REPORTED | 0 | ||||||||
| 118940772 | 11894077 | 6 | SS | RETROVIR | ZIDOVUDINE | 1 | Transplacental | 1 DF, UNK | U | 0 | 1 | DF | |||||||
| 118940772 | 11894077 | 7 | SS | RETROVIR | ZIDOVUDINE | 1 | Intravenous (not otherwise specified) | 6 MG/KG, QD | U | 0 | 6 | MG/KG | QD | ||||||
| 118940772 | 11894077 | 8 | SS | RETROVIR | ZIDOVUDINE | 1 | Oral | 8 MG/KG, QD | U | 0 | 8 | MG/KG | QD | ||||||
| 118940772 | 11894077 | 9 | SS | EPIVIR | LAMIVUDINE | 1 | Oral | 4 MG/KG, QD | U | 0 | 4 | MG/KG | QD | ||||||
| 118940772 | 11894077 | 10 | SS | INVIRASE | SAQUINAVIR MESYLATE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118940772 | 11894077 | 11 | C | LEXOMIL | BROMAZEPAM | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118940772 | 11894077 | 12 | C | ROHYPNOL | FLUNITRAZEPAM | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118940772 | 11894077 | 13 | C | SALBUTAMOL | ALBUTEROL | 1 | Transplacental | EXPOSURE INITIATD IN WEEK 32 OF GESTATION. | U | 0 | |||||||||
| 118940772 | 11894077 | 14 | C | TARDYFERON | FERROUS SULFATE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118940772 | 11894077 | 15 | C | IMODIUM | LOPERAMIDE HYDROCHLORIDE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118940772 | 11894077 | 16 | C | TITANOREINE | CARRAGEENANTITANIUMINC | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118940772 | 11894077 | 17 | C | OROKEN | CEFIXIME | 1 | Transplacental | UNK | U | 0 | |||||||||
| 118940772 | 11894077 | 18 | C | CLAMOXYL | AMOXICILLINCLAVULANIC ACID | 1 | Transplacental | 2 G, UNK | U | 0 | 2 | G | |||||||
| 118940772 | 11894077 | 19 | C | VIRACEPT | NELFINAVIR MESYLATE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118940772 | 11894077 | 1 | Product used for unknown indication |
| 118940772 | 11894077 | 2 | Product used for unknown indication |
| 118940772 | 11894077 | 3 | Product used for unknown indication |
| 118940772 | 11894077 | 4 | Product used for unknown indication |
| 118940772 | 11894077 | 5 | Product used for unknown indication |
| 118940772 | 11894077 | 6 | Product used for unknown indication |
| 118940772 | 11894077 | 7 | Prophylaxis |
| 118940772 | 11894077 | 9 | Prophylaxis |
| 118940772 | 11894077 | 10 | Product used for unknown indication |
| 118940772 | 11894077 | 11 | Product used for unknown indication |
| 118940772 | 11894077 | 12 | Product used for unknown indication |
| 118940772 | 11894077 | 13 | Product used for unknown indication |
| 118940772 | 11894077 | 14 | Product used for unknown indication |
| 118940772 | 11894077 | 15 | Product used for unknown indication |
| 118940772 | 11894077 | 16 | Product used for unknown indication |
| 118940772 | 11894077 | 17 | Product used for unknown indication |
| 118940772 | 11894077 | 18 | Product used for unknown indication |
| 118940772 | 11894077 | 19 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118940772 | 11894077 | OT |
| 118940772 | 11894077 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118940772 | 11894077 | Agitation | |
| 118940772 | 11894077 | Blood lactic acid increased | |
| 118940772 | 11894077 | Cytomegalovirus infection | |
| 118940772 | 11894077 | Febrile convulsion | |
| 118940772 | 11894077 | Foetal exposure during pregnancy | |
| 118940772 | 11894077 | Hepatosplenomegaly | |
| 118940772 | 11894077 | Hypertriglyceridaemia | |
| 118940772 | 11894077 | Hypocalcaemia | |
| 118940772 | 11894077 | Infection | |
| 118940772 | 11894077 | Rhinitis | |
| 118940772 | 11894077 | Speech disorder | |
| 118940772 | 11894077 | Splenomegaly |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118940772 | 11894077 | 2 | 199708 | 19980503 | 0 | |
| 118940772 | 11894077 | 6 | 19980503 | 0 | ||
| 118940772 | 11894077 | 18 | 20010503 | 0 |